ReportsnReports - The Outlook for Pharmaceuticals (BRIC, Asia, Europe, E7)

DALLAS, July 20, 2011 /PRNewswire/ --

ReportsnReports announces it will carry reports on The Outlook for Pharmaceuticals for BRIC, Central & South East Asia, Western, Northern, Central & Eastern Europe as well as E7 countries in its store

Espicom Limited's latest market research reports on the pharmaceutical market cover the outlook for pharmaceuticals in emerging E7 countries as well as Asian & European countries including but not limited to Brazil, Russia, India, China, Pakistan, Bangladesh,  Malaysia, Singapore, South Korea, Taiwan, Indonesia, Thailand, Hungary, Poland, Denmark, Finland, Lithuania, Norway, Sweden, France, Germany, Italy, Spain, Mexico, Turkey and United Kingdom.

Here is the list of available reports on The Outlook for Pharmaceuticals:

• The Outlook for Pharmaceuticals in Brazil, Russia, India & China
• The Outlook for Pharmaceuticals in Central Asia
• The Outlook for Pharmaceuticals in South East Asia
• The Outlook for Pharmaceuticals in Central & Eastern Europe
• The Outlook for Pharmaceuticals in Northern Europe
• The Outlook for Pharmaceuticals in Western Europe
• E7: The Outlook for Pharmaceuticals to 2012

These reports discuss the outlook for pharmaceuticals in these countries, highlights from each region, opportunities, if any and more. At $3490 each, these geo-targeted reports on the outlook for pharmaceuticals offer a range of information on the current status of these pharmaceutical markets and few projections & forecasts.

The emerging E7 countries represent the best prospect for growth. The potential of these countries is huge: they have a combined population of over three billion people, and their economies are performing very well. One consequence of this increasing wealth is a growing financial capacity to treat previously unmet health needs. Another is increasing incidence of 'affluence' diseases such as diabetes, as people live longer and have more sedentary lifestyles. The report on E7 pharmaceutical markets is projected to 2012.

Other Similar Pharmaceutical Market Report:

Co-promotion and Co-marketing Agreements in Pharma, Biotech and Diagnostics, 5th edition

This report provides details of the latest co-promotion and co-marketing agreements announced in the pharmaceutical, biotechnology and diagnostic sectors. Fully revised and updated, the report provides details of co-promotion and co-marketing agreements from 2005 to mid 2011.

The report provides a detailed understanding and analysis of how and why companies enter co-promotion and co-marketing deals. The majority of deals are multi-component whereby the licensor retains either a right or option to co-promote/market the resultant product of the research collaboration. There are also numerous pure co-promotion/marketing deals whereby the products originator takes on a co-promotion/marketing partner in order to maximize a products presence in the marketplace.

Read the complete 5^th edition report on co-promotion and co-marketing agreements in Pharma, Biotech and Diagnostics.

About Us

ReportsnReports comprises an online market research library of 90,000+ reports and in-depth studies of over 5000 micro markets. Our database includes reports by leading publishers from across the globe. We provide 24/7 online and offline support service to our customers.

Follow Us on Twitter: http://twitter.com/marketsreports

Our Facebook Page: http://www.facebook.com/pages/ReportsnReports/191441427571689

Contact:
Mr. Priyank
7557 Rambler road,
Suite 727, Dallas, TX 75231
Tel: +1-888-989-8004 EXT 106
http://www.reportsnreports.com/
Visit Our Market Research Blog

SOURCE ReportsnReports